Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Gordon, IJ  [Clear All Filters]
Journal Article
J. E. Ledgerwood, Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 306 St, DNA Priming and Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials, Lancet Infect Dis, vol. 11, pp. 916-924, 2011.
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., ,, Bailer, R. T., Roederer, M., Koup, R. A., Nabel, G. J., and Team, T. V. R. C. 008 St, DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-cell Responses After rAd5 Boost in a Randomized Clinical Trial, PLoS One, vol. 8, p. e59340, 2013.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L., Bailer, R. T., Roederer, M., Koup, R. A., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 011 St, Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (i.m.), Subcutaneous (s.c.) and Intradermal (i.d.) Administration (VRC 011), PLoS ONE, vol. 9, p. e91366, 2014.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., Graham, B. S., and Team, T. V. R. C. 201/20, Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals, Vaccine, vol. 25, pp. 1513-1525, 2007.
J. E. Martin, Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B., Andrews, C., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 301 St, A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial, Vaccine, vol. 26, pp. 6338-6343, 2008.
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., ,, Nabel, G. J., Graham, B. S., and Team, T. V. R. C. 303 St, A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial, J Infect Dis, vol. 203, pp. 1396-1404, 2011.